

FIRST TIME GENERIC APPROVAL

Brand Name	Emtriva®
Generic Name	emtricitabine
Drug Manufacturer	Cipla Limited

New Drug Approval

FDA approval date: July 2, 2018

Generic Manufacturer: Cipla Limited

Dosage form(s): 200 mg Capsules

Therapeutic equivalent code: AB

Indications for Use

Emtricitabine is indicated for:

- HIV-1 infection, treatment: Treatment of HIV-1 infection in combination with other antiretroviral agents.

This document is designed to be an informational resource to facilitate discussion and should be used neither as a basis for clinical decision-making or treatment nor as a substitute for reading original literature. RxAdvance makes every effort to ensure that the information provided is up-to-date, accurate, and complete, but no guarantee is made to that effect. If this information is provided to clients or vendors, it is subject to any contractual confidentiality provisions. Third-party disclosures are in violation of confidentiality provisions.